Apostrophe has been acquired by Hims & Hers Health, Inc.
The private shareholders of Apostrophe have sold the company to Hims & Hers Health, Inc.
Founded in 2012 and based in Oakland, California, Apostrophe is a direct-to-patient teledermatology platform that provides individuals with access to tailored, clinical-quality treatment plans that are prescribed by board-certified dermatologists. Through its vertically integrated in-house pharmacy, the company creates premium Apostrophe-branded products that use bespoke combinations of topical formulas and oral medications to meet the unique needs of patients. Driven by its innovative telehealth model, well-recognized skincare brand and visionary leadership team, the company has experienced rapid growth over the past several years.
Based in San Francisco, California, Hims & Hers is a leading multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers.
Oaklins’ team in Los Angeles acted as advisor to the private shareholders of Apostrophe in this transaction.
Contáctese con el equipo de la transacción
Adam Abramowitz
Oaklins Intrepid
Hayden Rosenthal
Oaklins Intrepid
Transacciones relacionadas
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Conozca másbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Conozca másBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Conozca más